Loading...
WuXi XDC Cayman Inc
2268.HK•HKSE
Healthcare
Medical - Diagnostics & Research
HK$44.80
HK$0.25(0.56%)
WuXi XDC Cayman Inc (2268.HK) Company Profile & Overview
Explore WuXi XDC Cayman Inc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
WuXi XDC Cayman Inc (2268.HK) Company Profile & Overview
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
SectorHealthcare
IndustryMedical - Diagnostics & Research
CEODr. Jincai Li Ph.D.
Contact Information
No. 11 Xinhui Ring Road, Wuxi
Company Facts
2,041 Employees
IPO DateJun 18, 2012
CountryCN
Actively Trading